Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03435939 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240
A Early Phase 1 study of Cystic Fibrosis, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT03435939: Active Early Phase 1 study of Cystic Fibrosis, sponsored by University of Kansas Medical Center.
NCT03435939 is a Early Phase 1 study of Cystic Fibrosis that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 16 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03435939, a Early Phase 1 study of Cystic Fibrosis, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies
Primary Outcome
Losartan (100 mg for \>12 weeks) will improve MCC+CC clearance in CF patients not on CFTR augmentation therapy in % of baseline
Conditions Studied
Interventions
- DRUG Losartan
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2026-02-28 |
| Phase | Early Phase 1 |
What the registry record for NCT03435939 still lists
NCT03435939 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Losartan is the first listed.
NCT03435939 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03435939 about?
NCT03435939 is a clinical study titled "Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240". The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies
What is the current status of trial NCT03435939?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2022-02-15. Estimated completion is 2026-02-28.
What conditions does trial NCT03435939 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT03435939?
The interventions under investigation include: Losartan (DRUG).
Who is sponsoring clinical trial NCT03435939?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03435939 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03435939's enrollment target sits among peer trials
16 140th of 169 higher than 26 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis
RECRUITING · Early Phase 1
-
Regional Monitoring of CF Lung Disease
RECRUITING · Early Phase 1
-
Personalized Theratyping Trial
RECRUITING · Early Phase 1
-
19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis
COMPLETED · Early Phase 1
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI